Brainsway (BWAY)
(Delayed Data from NSDQ)
$9.00 USD
-0.06 (-0.66%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $9.00 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.00 USD
-0.06 (-0.66%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $9.00 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth B Momentum B VGM
Zacks News
New Strong Sell Stocks for February 7th
by Zacks Equity Research
AMD, BWAY and DCOM have been added to the Zacks Rank #5 (Strong Sell) List on February 7, 2023.
New Strong Sell Stocks for February 1st
by Zacks Equity Research
BWAY, CMAX and EQBK have been added to the Zacks Rank #5 (Strong Sell) List on February 1, 2023.
New Strong Sell Stocks for January 30th
by Zacks Equity Research
BFC, CMAX and BWAY have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2023.
New Strong Sell Stocks for January 26th
by Zacks Equity Research
BWAY, INDB and CNX have been added to the Zacks Rank #5 (Strong Sell) List on January 26, 2023.
New Strong Sell Stocks for January 24th
by Zacks Equity Research
ABM, BWAY and DXPE have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2023.
New Strong Sell Stocks for January 19th
by Zacks Equity Research
ABM, BWAY and DXPE have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022.
New Strong Sell Stocks for January 10th
by Zacks Equity Research
BWAY, BWAY and AXL have been added to the Zacks Rank #5 (Strong Sell) List on January 10, 2023.
Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) Q2 performance will likely reflect continued strength in its dental and medical businesses.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Brainsway Ltd. Sponsored ADR (BWAY) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostics.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
Lantheus (LNTH) to Report Q2 Results: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) Q2 performance is likely to gain from the continued uptake of PYLARIFY and DEFINITY.
Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View
by Zacks Equity Research
Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.
Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Diagnostics base business organic volume is anticipated to have continued its rally in Q2, led by consistent growth in esoteric and routine procedures.
Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.
What's in Store for Thermo Fisher (TMO) in Q2 Earnings?
by Zacks Equity Research
The emergence of the new virus variants, through the months of Q2, is likely to have led to top-line contributions within Thermo Fisher's (TMO) Life-Science Solutions segment.
What's in Store for Boston Scientific (BSX) in Q2 Earnings?
by Zacks Equity Research
Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.
Wall Street Analysts Believe Brainsway Ltd. Sponsored ADR (BWAY) Could Rally 159%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 158.6% in Brainsway Ltd. Sponsored ADR (BWAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Brainsway Ltd. Sponsored ADR (BWAY) Stock Jumps 9.4%: Will It Continue to Soar?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.